Ratings by Cantor Fitzgerald (Eric Schmidt)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/17/2026 | Agios Pharma | AGIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/24/2026 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/23/2026 | Dyne Therapeutics | DYN | New Coverage | Overweight (N/A) |
23.21 (25.57) |
10.17% | Details | |
| 7/13/2026 | Immunocore Holdings | IMCR | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/8/2026 | Alumis Inc | ALMS | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/23/2026 | Crescent Biopharma Inc | CBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/22/2026 | Biogen | BIIB | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/18/2026 | Scholar Rock | SRRK | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/4/2026 | ADC Therapeutics | ADCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/3/2026 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/2/2026 | Bicara Therapeutics Inc | BCAX | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/2/2026 | Odyssey Therapeutics | ODTX | New Coverage | Overweight (N/A) |
16.96 (21.01) |
23.88% | Details | |
| 6/1/2026 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/27/2026 | Bicara Therapeutics Inc | BCAX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/22/2026 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/7/2026 | LeonaBio | LONA | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/6/2026 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/2/2026 | Generate Biomedicines | GENB | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/24/2026 | Generate Biomedicines | GENB | New Coverage | Overweight (N/A) |
12.52 (15.49) |
23.72% | Details | |
| 3/19/2026 | Scholar Rock | SRRK | Maintain | Overweight (N/A) |
|
Details | ||
| 3/12/2026 | Agios Pharma | AGIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/26/2026 | LeonaBio | LONA | New Coverage | Overweight (N/A) |
5.81 (8.14) |
40.1% | Details | |
| 1/12/2026 | Beam Therapeutics Inc | BEAM | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/19/2025 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/17/2025 | Legend Biotech Corp. | LEGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/11/2025 | Scholar Rock | SRRK | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/25/2025 | Agios Pharma | AGIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/20/2025 | Agios Pharma | AGIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/27/2025 | Tango Therapeutics Inc. | TNGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/20/2025 | Verastem | VSTM | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/20/2025 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/16/2025 | Verastem | VSTM | New Coverage | Overweight (N/A) |
9.40 (6.71) |
-28.62% | Details | |
| 10/9/2025 | Arcellx Inc. | ACLX | New Coverage | Neutral (N/A) |
88.29 (115.07) |
30.33% | Details | |
| 8/14/2025 | Alumis Inc | ALMS | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/13/2025 | BridgeBio Oncology Therapeutics, In | BBOT | New Coverage | Overweight (N/A) |
0.00 (9.22) |
0% | Details | |
| 7/28/2025 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/17/2025 | Scholar Rock | SRRK | New Coverage | Overweight (N/A) |
41.15 (52.16) |
26.76% | Details | |
| 6/27/2025 | Avidity Biosciences | RNA | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/24/2025 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/20/2025 | Prothena Corp | PRTA | Maintain | Neutral (Neutral) |
|
Details | ||
| 6/10/2025 | Cidara Therapeutics | CDTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/3/2025 | Bicara Therapeutics Inc | BCAX | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/2/2025 | Bicara Therapeutics Inc | BCAX | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/2/2025 | Immatics | IMTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/2/2025 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/13/2025 | Agios Pharma | AGIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/2/2025 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/23/2025 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/15/2025 | Cidara Therapeutics | CDTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/10/2025 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/1/2025 | Immatics | IMTX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/31/2025 | Bicara Therapeutics Inc | BCAX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/31/2025 | Avidity Biosciences | RNA | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/27/2025 | Summit Therapeutics plc | SMMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/21/2025 | Summit Therapeutics plc | SMMT | New Coverage | Overweight (N/A) |
19.44 (12.48) |
-35.8% | Details | |
| 3/20/2025 | Alumis Inc | ALMS | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/13/2025 | Bicara Therapeutics Inc | BCAX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/28/2025 | Avidity Biosciences | RNA | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/5/2025 | Biogen | BIIB | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/27/2025 | Cidara Therapeutics | CDTX | New Coverage | Overweight (N/A) |
18.91 (221.38) |
1070.7% | Details | |
| 10/8/2024 | Bicara Therapeutics Inc | BCAX | New Coverage | Overweight (N/A) |
24.45 (24.32) |
-0.53% | Details | |
| 7/23/2024 | Alumis Inc | ALMS | New Coverage | Overweight (N/A) |
13.00 (25.42) |
95.54% | Details | |
| 5/30/2024 | ADC Therapeutics | ADCT | New Coverage | Overweight (N/A) |
3.33 (0.97) |
-70.87% | Details | |
| 4/23/2024 | Incyte | INCY | New Coverage | Neutral (N/A) |
51.92 (121.78) |
134.55% | Details | |
| 4/4/2024 | Tango Therapeutics Inc. | TNGX | New Coverage | Overweight (N/A) |
7.68 (25.63) |
233.72% | Details | |
| 3/14/2024 | Avidity Biosciences | RNA | New Coverage | Overweight (N/A) |
24.83 (12.48) |
-49.74% | Details | |
| 2/8/2024 | Agios Pharma | AGIO | Maintain | Overweight (N/A) |
|
Details | ||
| 12/20/2023 | Biogen | BIIB | New Coverage | Overweight (N/A) |
251.69 (209.07) |
-16.93% | Details | |
| 11/9/2023 | Gracell Biotechnologies Inc | GRCL | New Coverage | Overweight (N/A) |
4.40 (10.25) |
132.95% | Details | |
| 11/2/2023 | Immatics | IMTX | New Coverage | Overweight (N/A) |
7.80 (9.42) |
20.77% | Details | |
| 11/2/2023 | Immunocore Holdings | IMCR | New Coverage | Overweight (N/A) |
45.37 (34.11) |
-24.82% | Details | |
| 10/17/2023 | bluebird bio | BLUE | New Coverage | Neutral (N/A) |
2.80 (4.97) |
77.5% | Details |
